5. Repros Reproach
Markets were closed last Friday in honor of Good Friday. Luckily for us, Repros Therapeutics (RPRX) CEO Joe Podolski generously provided more than enough dumbness last Thursday to tide us through the long holiday weekend.
On a conference call last Thursday morning, Podolski told analysts that his experimental testosterone drug Androxal helped gay Cubans have more sex. The gay Cubans entered the clinical trial with low testosterone, according to Podolski, yet after taking Androxal, their testosterone levels soared, leading to lots and lots and lots of sex.
Seriously, we're not joking. We may kid about a lot of things, but gay Cuban sex is not one of them.Anyway, Podolski said the gay Cuban men had so much sex that it caused their sperm counts to drop precipitously. But he urged the crowd not to blame the plunge on Androxal. Podolski maintained instead that the lower sperm counts were the result of the gay Cubans having so much sex that their ammunition ran low.
What more can we say Dumbest fans? Res ipsa loquitur . And if that wasn't enough, TheStreet's Adam Feuerstein reported that at another point during the conference call, Podolski disclosed that a nurse at one of the Androxal clinical trial sites fabricated baseline sperm counts for patients. When Repros discovered the data fraud, the company changed the fishy numbers and everything turned out fine. A second phase III study of Androxal is under way with enrollment expect to wrap in May. Podolski insisted the data announced Thursday should convince investors that the second study will also be positive. Repros bulls are probably looking forward to the next report and not just for its racy content. Shares of the stock spiked nearly 80% on Podolski's pronouncements despite the trial's inconsistencies and the missing Androxal data. Then again, fundamentals aren't really a factor when it comes to Repros stock. Nearly half the company's shares have been sold short, opening up the possibility for the bulls to once again squeeze the bears where it hurts. And that can't be good for their sperm counts either.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV